Data / Drug companies / Actavis Pharma, Inc.
Actavis Pharma, Inc.: 87 products in the FDA NDC directory, labeler code 0228
Actavis Pharma, Inc. (labeler code 0228) lists 87 products in the FDA National Drug Code Directory, covering 20 finished drugs by generic name. By type: 67 prescription drugs, 20 drugs for further processing. Its main marketing category is generic drugs (ANDA). The newest product started marketing on February 14, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0228
- Products in commercial distribution
- 87
- Packages
- 119
- Finished drugs by generic name
- 20
- Prescription products
- 67
- Over the counter products
- 0
- Controlled substance products
- Schedule II 12, Schedule III 4, Schedule IV 20
- Flagged as original packager
- 57 of 57 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 13
- Earliest marketing start
- September 30, 1990
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 65 | 74.7% |
| Drugs for further processing | 20 | 23% |
| Authorized generics (NDA) | 2 | 2.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 67 | 77% |
| Drugs for further processing | 20 | 23% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Alprazolam | 8 | 37 |
| Morphine sulfate | 6 | 31 |
| Ropinirole | 5 | 20 |
| Propranolol hydrochloride | 4 | 51 |
| Clonidine hydrochloride | 4 | 45 |
| Guanfacine | 4 | 33 |
| Lamotrigine | 4 | 51 |
| Oxazepam | 3 | 6 |
| Duloxetine | 3 | 36 |
| Doxepin | 2 | 8 |
| Isosorbide mononitrate | 2 | 25 |
| Buprenorphine and naloxone | 2 | 22 |
| Temazepam | 2 | 28 |
| Diclofenac sodium | 2 | 109 |
| Buprenorphine | 2 | 24 |
| Fluvoxamine maleate | 2 | 16 |
| Pilocarpine hydrochloride | 2 | 14 |
| Indapamide | 2 | 10 |
| Diltiazem hydrochloride | 1 | 55 |
| Hydrochlorothiazide | 1 | 51 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule, extended release | 21 | 24.1% |
| Tablet | 20 | 23% |
| Tablet, film coated | 12 | 13.8% |
| Tablet, film coated, extended release | 9 | 10.3% |
| Capsule, delayed release pellets | 6 | 6.9% |
| Capsule, gelatin coated | 6 | 6.9% |
| Tablet, extended release | 5 | 5.7% |
| Tablet, orally disintegrating | 4 | 4.6% |
| Capsule | 2 | 2.3% |
| Tablet, delayed release | 2 | 2.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Fluvoxamine maleate | 0228-2849 | Capsule, extended release | Drugs for further processing | February 14, 2025 |
| Fluvoxamine maleate | 0228-2848 | Capsule, extended release | Drugs for further processing | February 14, 2025 |
| Duloxetine | 0228-2892 | Capsule, delayed release pellets | Drugs for further processing | February 1, 2024 |
| Duloxetine | 0228-2891 | Capsule, delayed release pellets | Drugs for further processing | February 1, 2024 |
| Duloxetine | 0228-2890 | Capsule, delayed release pellets | Drugs for further processing | February 1, 2024 |
| Oxazepam | 0228-2073 | Capsule, gelatin coated | Drugs for further processing | September 29, 2023 |
| Oxazepam | 0228-2069 | Capsule, gelatin coated | Drugs for further processing | September 29, 2023 |
| Oxazepam | 0228-2067 | Capsule, gelatin coated | Drugs for further processing | September 29, 2023 |
| Doxepin | 0228-3316 | Tablet, film coated | Drugs for further processing | August 25, 2023 |
| Doxepin | 0228-3315 | Tablet, film coated | Drugs for further processing | August 25, 2023 |
| Indapamide | 0228-2597 | Tablet, film coated | Drugs for further processing | May 16, 2023 |
| Indapamide | 0228-2571 | Tablet, film coated | Drugs for further processing | May 16, 2023 |
| Isosorbide mononitrate | 0228-2631 | Tablet | Drugs for further processing | February 7, 2023 |
| Isosorbide mononitrate | 0228-2620 | Tablet | Drugs for further processing | February 7, 2023 |
| Doxepin | 0228-3316 | Tablet, film coated | Generic drugs (ANDA) | January 2, 2020 |
| Doxepin | 0228-3315 | Tablet, film coated | Generic drugs (ANDA) | January 2, 2020 |
| Lamotrigine | 0228-1638 | Tablet, film coated, extended release | Generic drugs (ANDA) | June 1, 2016 |
| Lamotrigine | 0228-1580 | Tablet, film coated, extended release | Generic drugs (ANDA) | April 1, 2016 |
| Lamotrigine | 0228-1453 | Tablet, film coated, extended release | Generic drugs (ANDA) | April 1, 2016 |
| Lamotrigine | 0228-1422 | Tablet, film coated, extended release | Generic drugs (ANDA) | April 1, 2016 |
| Alprazolam | 0228-2039 | Tablet | Drugs for further processing | July 30, 2015 |
| Alprazolam | 0228-2031 | Tablet | Drugs for further processing | July 30, 2015 |
| Alprazolam | 0228-2029 | Tablet | Drugs for further processing | July 30, 2015 |
| Alprazolam | 0228-2027 | Tablet | Drugs for further processing | July 30, 2015 |
| Clonidine Hydrochloride | 0228-4241 | Tablet, extended release | Generic drugs (ANDA) | June 17, 2015 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.